Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 100,000 | $11,060,000 | -62% | 0.07% |
| 2. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 75,881 | $8,392,439 | +12% | 3.71% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 4,500 | $497,700 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.20 | 30,000 | Director | 37,491 | 2025-05-05 | Filing | |
| $116.80 | 755 | Officer | 20,190 | 2025-02-13 | Filing | |
| $116.77 | 796 | Officer | 19,544 | 2025-02-13 | Filing | |
| $116.68 | 3,012 | Director | 524,209 | 2025-02-13 | Filing | |
| $116.69 | 2,832 | Director | 521,618 | 2025-02-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,682,394 | $1,623,872,774 | 0.03% | |
| 2. | 9,941,887 | $1,099,572,701 | 0.02% | |
| 3. | 895,542 | $99,046,999 | 0.14% | |
| 4. | 828,682 | $91,652,264 | 0.02% | |
| 5. | 804,466 | $88,973,940 | 0.06% |
News See All
Billionaire Cliff Asness' 10 Stock Picks with Huge Upside Potential
Cliff Asness, the founder, managing principal, and chief investment officer of AQR Capital Management, is a well-known figure in the world of finance.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
15 Best Fast Growth Stocks To Buy Right Now
In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market expectations of 2.7% and a deceleration from the 3.1% growth observed in the...
10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025Neurocrine Biosciences, Inc. misses on earnings expectations.
12 Best Low Risk High Growth Stocks to Invest In
In the past few days, the reintroduction of tariffs by the US government has been a significant factor influencing market dynamics.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript October 30, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.